Payment overview · 2025
General Payments
$989.97
51 reported records · 17 companies
Healthcare provider profile · identity verified
Tyler James Rushforth
Allopathic & Osteopathic Physicians|Family Medicine · CULLMAN, AL · NPI 1114436219
Verified facts
What the public records show
CMS Open Payments records show Tyler James Rushforth received $989.97 in general payments during 2025 across 51 reported records.
ABBVIE INC. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Nurtec Odt, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $192.80 | 19.5% | 14 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $179.18 | 18.1% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $131.22 | 13.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $92.87 | 9.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.48 | 6.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.89 | 5.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.16 | 5.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $44.03 | 4.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.13 | 3.4% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $24.41 | 2.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.35 | 2.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.32 | 2.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.82 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.38 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.66 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.44 | 1.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.83 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $989.97 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $192.80 | 14 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $179.18 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $131.22 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $92.87 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.48 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.89 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $44.03 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 237 | 55 |
| Gabapentin | Gabapentin | 211 | 72 |
| Omeprazole | Omeprazole | 195 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 173 | 65 |
| Montelukast Sodium | Montelukast Sodium | 171 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 49 |
| Lisinopril | Lisinopril | 165 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 58 |
| Losartan Potassium | Losartan Potassium | 146 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 48 |
| Trazodone Hcl | Trazodone Hcl | 129 | 47 |
| Furosemide | Furosemide | 125 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 31 |
| Eliquis | Apixaban | 92 | 21 |
| Simvastatin | Simvastatin | 86 | 32 |
| Famotidine | Famotidine | 84 | 33 |
| Potassium Chloride | Potassium Chloride | 82 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 26 |
| Clonazepam | Clonazepam | 73 | 13 |
| Buspirone Hcl | Buspirone Hcl | 71 | 24 |
| Alprazolam | Alprazolam | 67 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 25 |
| Prednisone | Prednisone | 65 | 46 |
| Jardiance | Empagliflozin | 63 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 25 |
| Ondansetron Odt | Ondansetron | 61 | 23 |
| Azithromycin | Azithromycin | 60 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 22 |
| Carvedilol | Carvedilol | 57 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 18 |
| Mirtazapine | Mirtazapine | 54 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 21 |
| Cefdinir | Cefdinir | 51 | 38 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 15 |
| Metformin Hcl | Metformin Hcl | 50 | 24 |
| Donepezil Hcl | Donepezil Hcl | 48 | 20 |
| Sertraline Hcl | Sertraline Hcl | 48 | 17 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 12 |
| Tramadol Hcl | Tramadol Hcl | 46 | 14 |
| Pregabalin | Pregabalin | 45 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Methocarbamol | Methocarbamol | 44 | 17 |
| Meloxicam | Meloxicam | 43 | 20 |
| Alendronate Sodium | Alendronate Sodium | 42 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 14 |
| Ozempic | Semaglutide | 39 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 15 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 16 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 13 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 14 |
| Topiramate | Topiramate | 25 | 11 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | 11 |
| Spironolactone | Spironolactone | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Atenolol | Atenolol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $989.97 · 51 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, FANAPT, JATENZO, JOURNAVX, KRYSTEXXA, Kerendia, MINIMED 780G, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, Veozah, XYOSTED, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error